Skip to main content
Premium Trial:

Request an Annual Quote

Precision Therapeutics, Amnis, Purdue, and Genoptix Win US Patents

Premium

Precision Therapeutics has been awarded US Patent No. 6,933,129, "Method for culturing and assaying cells."

Paul Kornblith is the sole inventor listed on the patent.

According to its abstract, the patent protects a system for screening a multiple of candidate therapeutic or chemotherapeutic agents for efficacy as to a specific patient, in which a tissue sample from the patient is harvested, cultured, and separately exposed to a plurality of treatments and/or therapeutic agents for the purpose of objectively identifying. One particularly important tissue sample preparation technique is the initial preparation of cohesive multi-cellular particulates of the tissue sample, the abstract states. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer term inhibitory effect of a given anti-cancer agent are investigated. The tissue sample technique is also useful in assaying expression and/or secretion of various markers, factors, or antigens present on or produced by the cultured cells for diagnostic purposes and for using such expression to monitor the applicability of certain candidate therapeutic or chemotherapeutic agents and the progress of treatment with those agents, the abstract states.


Amnis Corporation has been awarded US Patent No. 6,934,408, "Method and apparatus for reading reporter labeled beads."

Inventors listed on the patent are Keith Frost, David Basiji, Richard Bauer, Rosalynde Finch, William Ortyn, and David Perry.

According to its abstract, the patent protects a method whereby combinatorially synthesized DNA oligonucleotides attached to encoded beads, and hybridized to amplified and labeled genomic DNA or RNA, are analyzed using a flow imaging system. Oligonucleotides and corresponding reporters are bound to the surfaces of a plurality of small beads such that different beads bear different oligo sequences, the abstract states. Each bead bears a unique optical signature comprising a predefined number of unique reporters, where each reporter comprises a predefined combination of different fluorochromes. The composite spectral signature in turn identifies the unique nucleotide sequence of its attached oligo chains. This optical signature is rapidly decoded using an imaging system to discriminate the different reporters attached to each bead in a flow in regard to color and spatial position on the bead, the abstract states.


Purdue Research Foundation has been awarded US Patent No. 6,935,165, "Microscale sensor element and related device and method of use."

Inventors listed on the patent are Rashid Bashir, Nicholas Peppas, James Hilt, and Amit Gupta.

According to its abstract, the patent protects a monitoring apparatus useful in detecting viability of biological cells. A substrate defines a microscopic chamber, and one or more microcantilevers extend from the substrate into the chamber. A detector is operatively connected to the microcantilevers for sensing a state of deformation thereof. On each microcantilever is deposited a layer of an environmentally sensitive hydrogel polymer having a configuration changing in accordance with presence of an environmental parameter, the abstract states.


Genoptix has been awarded US Patent No. 6,939,811, "Method for separating micro-particles."

Osman Kibar is the sole inventor listed on the patent.

According to its abstract, the patent protects a system and method for separating particles in which the particles are exposed to a moving light intensity pattern which causes them to move at different velocities based on their physical properties. This system and method allows particles of similar size and shape to be separated based on differences in their dielectric properties, the abstract states.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.